# US 2014/0371294 A1 · Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0371294 A1
- Document ID: US20140371294A1
- Status: Published application
- Kind: A1
- Application number: 14/262,272
- Filed: 2014-04-25
- Published: 2014-12-18
- Earliest claimed: 2009-03-16
- Assignees: aTyr Pharma, Inc.; Pangu BioPharma Limited
- Applicants: aTyr Pharma, Inc.; Pangu BioPharma Limited
- Inventors: Jie Zhou; Ching-Fun Lau; Zhiwen Xu; Wing-Sze Lo; Kristi Helen Piehl; Leslie Ann Greene
- Web page: https://patentgrep.com/patent/US20140371294A1

## CPC

- C07K 16/40: against enzymes
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/93: {Ligases (6)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Y 601/01021: Histidine-tRNA ligase (6.1.1.21)
- G01N 33/573: for enzymes or isoenzymes
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/156: Polymorphic or mutational markers
- G01N 2333/9015: Ligases (6)
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2500/10: involving cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

## Claims

### Claim at position 1

1-49. (canceled)

### Claim 50

A synthetic polynucleotide selected from (a) a polynucleotide that specifically hybridizes to a splice junction that is unique to a histidyl-tRNA synthetase (HRS) polynucleotide selected from SEQ ID NO:5, 8, and 10; and (b) a polynucleotide that encodes a HRS splice variant polypeptide of SEQ ID NO:6, 9, or 11 or a variant thereof having at least 95% identity along its length to SEQ ID NO:6, 9, or 11.

### Claim 51 (depends on 50)

The synthetic polynucleotide of claim 50, which is single-stranded.

### Claim 52 (depends on 50)

The synthetic polynucleotide of claim 50, which is double-stranded.

### Claim 53 (depends on 50)

The synthetic polynucleotide of claim 50, which is DNA or an analog thereof.

### Claim 54 (depends on 50)

The synthetic polynucleotide of claim 50, which is RNA or an analog thereof.

### Claim 55 (depends on 50)

The synthetic polynucleotide of claim 50, where the polynucleotide of (a) is fully complementary to the splice junction.

### Claim 56 (depends on 50)

The synthetic polynucleotide of claim 50, where the polynucleotide of (b) comprises SEQ ID NO:5, 8, or 10, or a variant thereof that comprises non-naturally-occurring codon(s).

### Claim 57 (depends on 50)

The synthetic polynucleotide of claim 50, where the polynucleotide of (b) comprises SEQ ID NO:5, 8, or 10.

### Claim 58 (depends on 50)

The synthetic polynucleotide of claim 50, wherein the polynucleotide of (a) is selected from a synthetic primer, probe, antisense oligonucleotide, and an RNA interference (RNAi) agent.

### Claim 59 (depends on 58)

The synthetic polynucleotide of claim 58, where the primer or probe consists of a sequence that is complementary to about 10-150 nucleotides of SEQ ID NO:5, 8, or 10.

### Claim 60 (depends on 59)

The synthetic polynucleotide of claim 59, where the primer or probe consists of a sequence that is complementary to about 10-15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or 150 nucleotides of SEQ ID NO:5, 8, or 10.

### Claim 61 (depends on 50)

A kit, comprising a container with a synthetic polynucleotide of claim 50.

### Claim 62 (depends on 50)

A pharmaceutical composition, comprising a synthetic polynucleotide of claim 50 and a pharmaceutically-acceptable carrier, where the composition is sterile and pyrogen-free.

### Claim 63

A recombinant vector, comprising a polynucleotide selected from (a) a polynucleotide that specifically hybridizes to a splice junction that is unique to a histidyl-tRNA synthetase (HRS) polynucleotide selected from SEQ ID NO:5, 8, and 10; and (b) a polynucleotide that encodes a HRS splice variant polypeptide of SEQ ID NO:6, 9, or 11 or a variant thereof having at least 95% identity along its length to SEQ ID NO:6, 9, or 11, wherein the polynucleotide is operably linked to a transcriptional regulatory element.

### Claim 64 (depends on 63)

The recombinant vector of claim 63, where the polynucleotide of (b) comprises SEQ ID NO:5, 8, or 10, or a variant thereof that comprises non-naturally-occurring codon(s).

### Claim 65 (depends on 64)

The recombinant vector of claim 64, where the polynucleotide of (b) comprises SEQ ID NO:5, 8, or 10.

### Claim 66 (depends on 63)

A pharmaceutical composition, comprising a recombinant vector of claim 63 and a pharmaceutically-acceptable carrier, where the composition is sterile and pyrogen-free.
